Uni-Bio Science Group’s BOSHUTAI® (Acarbose Tablets) successfully selected for Henan thirteen provinces alliance procurement

(Stock Code: 00690.HK)

Uni-Bio Science Group’s BOSHUTAI® (Acarbose Tablets)

successfully selected for Henan thirteen provinces alliance procurement

[2nd June 2022 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”; Stock code: 00690.HK) is pleased to announce that its wholly-owned subsidiary Beijing Genetech Pharm Limited  (Beijing  Genetech)  participated  in the  drug  alliance  procurement  of the  thirteen provinces (districts, cities, and corps) of Henan, Shanxi, Mongolia, Hubei, Hunan, Guangxi, Hainan, Chongqing, Guizhou, Qinghai, Ningxia and New Corps (the 13-provinces Alliance Procurement) for the second and fourth batches of medicines. These two batches of medicine’s original national procurement agreements have expired and bidding was open to the market to determine the continuation of procurement contracts in a centralized manner starting on June 1, 2022. After the 13-province Alliance Procurement Office opened the bid, Beijing Genetech 's Acarbose Tablets (trade name: BOSHUTAI®) successfully won the bid, with the proposed price of 0.3276 yuan per tablet.

There were 14 companies participating for the procurement of acarbose this time, and 8 companies were ultimately selected. Beijing Genetech was successfully selected at a good price, allowing affordable treatment for patients, whilst enabling a reasonable return-on-investment for the company. The total procurement demand for acarbose in the alliance provinces is about 908 million tablets (converted to 50mg in a unified way), and the procurement validity period is set at 2 years.

Picture: BOSHUTAI® product picture

In addition, the originator of acarbose, which is also the manufacturer with the largest procurement volume of approximately 469 million tablets (unified conversion to 50mg) in the 13-province alliance, did not win the bid. Hence, giving the Group an opportunity to quickly open for in-hospital sales, increase market share, and bring new opportunities for the future development of the company's acarbose products, which is another milestone in the successful commercialization of the company's products in the field of metabolic diseases.

It is also worth mentioning that in last year's fourth batch of national drugs centralized procurement, Beijing Genetech 's antifungal drug Voriconazole Tablets (trade name: PINUP®) also stood out from the competition, taking the first place in procurement volume. To satisfy the massive volumes of both products, Beijing Genetech successfully received MAH approval in May 2022 to manufacture Acarbose in Suzhou No. 4 Pharmaceutical Factory site, and thus significantly increasing Group’s supply chain security to the market going forward.

-End-

About BOSHUTAI® (Acarbose Tablets)

BOSHUTAI® is the trade name of the acarbose tablets developed by Uni-Bio Science Group, which comes in two dosage strengths, 50mg/tablet and 100mg/tablet. Acarbose is clinically indicated for impaired glucose tolerance and diabetes type 2 patients to decrease post-prandial glucose level, listed as a first line therapeutic drug in the China Diabetes Prevention and Therapy Guide 2017, and listed as one of drugs in the National Essential Medicine List and National Basic Medical Insurance. Acarbose inhibits alpha glucosidase in the intestine to decrease glucose absorption, which is particularly suitable for Asian patients whom have high carbohydrate diets. According to International Diabetes Federation data, as of 2019, the total number of people with diabetes in China is about 116.4 million among people aged 20 to 79. The PRC diabetes drug market is expected to continue to grow quickly in the coming ten years due to drivers such as aging population, increasing diagnosis and treatment rate, and growing importance of chronic disease drug by the medical insurance policy in China.

About Uni-Bio Science Group

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology and dermatology. Please visit the official website of Uni-Bio Science Group for more information:www.uni-bioscience.com。

For further information, please contact:

E-mail:ir@uni-bioscience.com